News

Coastar Therapeutics to Present in JP Morgan Conference Events

SAN DIEGO, January 5, 2023 – Coastar Therapeutics Inc., a biotechnology company developing novel delivery technologies to supercharge cell and gene therapies, announced that it will be presenting at events of the 42nd JP Morgan Healthcare Conference, January 8-11 in San Francisco. 

Coastar’s innovative cell membrane coating technology platform enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease targets. The technology can lead to increased efficacy, reduced toxicity, lower cost and more applications in cancers and other diseases.

“We are truly excited to be presenting during the JP Morgan week of events.” said Eddie Y. Chung, CEO of Coastar Therapeutics, “In the past 12 months, the Coastar team has made tremendous progress in developing our erythrocyte membrane based gene delivery platform. From local injection to systemic delivery, from viral to non-viral payloads, from oncology to gene therapy, we are generating important data and achieved great levels of efficacy and precision in delivery. I look forward to meeting and sharing our progress with colleagues and partners at JPM.”

“JPM is the week of premier events where the entire industry convenes and deals are made,” said Dr. Chongyang Luo, Chief Operating Officer of Coastar, “We are excited to meet up with our current and prospective partners. The industry realizes that effective and targeted gene delivery is a bottleneck to better and cost-effective therapies. Coastar is on track to break the bottleneck and supercharge cell and gene therapy.”

ABOUT COASTAR THERAPEUTICS

Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary ENHEnSTM  and eLNPTM   technology can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully targeted to tumor or other disease sites. The company is working with a number of global partners to help deliver their drugs.